Targeting FABP4 to Inhibit AGEs-RAGE/NF-κB Signalling Effectively Ameliorates Nucleus Pulposus Dysfunction and Angiogenesis in Obesity-Related Intervertebral Disc Degeneration

Abstract

Intervertebral disc degeneration (IVDD) is a primary contributor to low back pain, posing significant social and economic burdens. Increasing evidence shows that obesity contributes to IVDD, yet the underlying mechanisms remain elusive. Here, we firstly revealed a causal correlation between obesity and IVDD via a two-sample mendelian randomization analysis and identified fatty acid-binding protein 4 (FABP4) as the potential regulator to associate IVDD and obesity. Elevated FABP4 expression promoted extracellular matrix (ECM) disequilibrium and angiogenesis to exacerbate IVDD progression. Genetically knocking out or pharmacologically inhibiting FABP4 in high-fat diet-induced mice alleviated IVDD. Mechanistically, obesity activated the mammalian target of rapamycin complex 1 (mTORC1), which upregulated FABP4 expression, leading to the accumulation of advanced glycation end-products (AGEs) in intervertebral disc tissue. AGEs further activated the NF-κB signalling pathway, exacerbating ECM degradation and neovascularization. Conversely, rapamycin-mediated inhibition of mTORC1 suppressed FABP4 expression in nucleus pulposus cells (NPCs), alleviating IVDD in vivo. Collectively, our findings reveal a critical role of the obesity-induced mTORC1-FABP4 axis in ECM degradation and angiogenesis during IVDD progression. Targeting FABP4 may represent a promising therapeutic strategy for IVDD in obese individuals.

Keywords

angiogenesis / ECM homeostasis / FABP4 / intervertebral disc degeneration / mendelian randomization / obesity / signal pathway / therapeutic target

References

[1] M. V. Risbud and I. M. Shapiro, “Role of Cytokines in Intervertebral Disc Degeneration: Pain and Disc Content,” Nature Reviews Rheumatology 10, no. 1 (2014): 44-56.

[2] V. Francisco, J. Pino, M. Á. González-Gay, et al., “A New Immunometabolic Perspective of Intervertebral Disc Degeneration,” Nature Reviews Rheumatology 18, no. 1 (2022): 47-60.

[3] F. Cannata, G. Vadalà, L. Ambrosio, et al., “Intervertebral Disc Degeneration: A Focus on Obesity and Type 2 Diabetes,” Diabetes/Metabolism Research and Reviews 36, no. 1 (2020): e3224.

[4] N. Zielinska, M. Podgórski, R. Haładaj, M. Polguj, and Ł. Olewnik, “Risk Factors of Intervertebral Disc Pathology-A Point of View Formerly and Today-A Review,” Journal of Clinical Medicine 10 (2021): 409.

[5] L. Gou and Q. Zheng, “How to Reduce the Risk of Cervicalgia and Low Back Pain in Obese Individuals: A Mendelian Randomization Study,” Medicine 102 (2023): e33710.

[6] M. Rade, J. H. Määttä, M. B. Freidin, O. Airaksinen, J. Karppinen, and F. Williams, “Vertebral Endplate Defect as Initiating Factor in Intervertebral Disc Degeneration: Strong Association Between Endplate Defect and Disc Degeneration in the General Population,” Spine (Phila Pa 1976) 43, no. 6 (2018): 412-419.

[7] H. H. Chen, H. T. Hsu, M. H. Liao, and M. S. Teng, “Effects of Sex and Obesity on LEP Variant and Leptin Level Associations in Intervertebral Disc Degeneration,” International Journal of Molecular Sciences 23, no. 20 (2022): 12275.

[8] X. Lu, D. Li, H. Wang, et al., “Biomechanical Effects of Interbody Cage Height on Adjacent Segments in Patients With Lumbar Degeneration: A 3D Finite Element Study,” Journal of Orthopaedic Surgery and Research 17 (2022): 325.

[9] S. Hao, S. Zhang, J. Ye, et al., “Goliath Induces Inflammation in Obese Mice by Linking Fatty Acid β-Oxidation to Glycolysis,” EMBO Reports 24 (2023): e56932.

[10] R. K. Zwick, C. F. Guerrero-Juarez, V. Horsley, and M. V. Plikus, “Anatomical, Physiological, and Functional Diversity of Adipose Tissue,” Cell Metabolism 27, no. 1 (2018): 68-83.

[11] A. Y. Lee, S. M. Christensen, N. Duong, et al., “Sirt3 Pharmacologically Promotes Insulin Sensitivity Through PI3/AKT/mTOR and Their Downstream Pathway in Adipocytes,” International Journal of Molecular Sciences 23 (2022): 3740.

[12] J. Sellers, A. Brooks, S. Fernando, et al., “Fasting-Induced Upregulation of MKP-1 Modulates the Hepatic Response to Feeding,” Nutrients 13 (2021): 3941.

[13] W. Lai, M. Shi, R. Huang, P. Fu, and L. Ma, “Fatty Acid-Binding Protein 4 in Kidney Diseases: From Mechanisms to Clinics,” European Journal of Pharmacology 931 (2022): 175224.

[14] X. Huang, Y. Zhou, Y. Sun, and Q. Wang, “Intestinal Fatty Acid Binding Protein: A Rising Therapeutic Target in Lipid Metabolism,” Progress in Lipid Research 87 (2022): 101178.

[15] G. S. Hotamisligil and D. A. Bernlohr, “Metabolic Functions of FABPs - Mechanisms and Therapeutic Implications,” Nature Reviews. Endocrinology 11 (2015): 592-605.

[16] M. Kudo, M. Gao, M. Hayashi, Y. Kobayashi, J. Yang, and T. Liu, “Ilex Paraguariensis A.St.-Hil. Improves Lipid Metabolism in High-Fat Diet-Fed Obese Rats and Suppresses Intracellular Lipid Accumulation in 3T3-L1 Adipocytes via the AMPK-Dependent and Insulin Signaling Pathways,” Food & Nutrition Research 68 (2024), https://doi.org/10.29219/fnr.v68.10307.

[17] X. Fan, M. Xu, Q. Ren, et al., “Downregulation of Fatty Acid Binding Protein 4 Alleviates Lipid Peroxidation and Oxidative Stress in Diabetic Retinopathy by Regulating Peroxisome Proliferator-Activated Receptor γ-Mediated Ferroptosis,” Bioengineered 13, no. 4 (2022): 10540-10551, https://doi.org/10.1080/21655979.2022.2062533.

[18] B. Wang, J. Xu, Q. Ren, et al., “Fatty Acid-Binding Protein 4 Is a Therapeutic Target for Septic Acute Kidney Injury by Regulating Inflammatory Response and Cell Apoptosis,” Cell Death & Disease 13 (2022): 333.

[19] L. Yengo, J. Sidorenko, K. E. Kemper, et al., “Meta-Analysis of Genome-Wide Association Studies for Height and Body Mass Index in ∼700000 Individuals of European Ancestry,” Human Molecular Genetics 27, no. 20 (2018): 3641-3649.

[20] S. Chen, X. Wu, Y. Lai, et al., “Kindlin-2 Inhibits Nlrp3 Inflammasome Activation in Nucleus Pulposus to Maintain Homeostasis of the Intervertebral Disc,” Bone Research 10, no. 1 (2022): 5, https://doi.org/10.1038/s41413-021-00179-5.

[21] K. Sun, C. Yan, X. Dai, et al., “Catalytic Nanodots-Driven Pyroptosis Suppression in Nucleus Pulposus for Antioxidant Intervention of Intervertebral Disc Degeneration,” Advanced Materials 36, no. 19 (2024): e2313248.

[22] M. L. Ji, H. Jiang, X. J. Zhang, et al., “Preclinical Development of a microRNA-Based Therapy for Intervertebral Disc Degeneration,” Nature Communications 9 (2018): 5051.

[23] X. Chen, K. Chen, J. Hu, et al., “Palmitic Acid Induces Lipid Droplet Accumulation and Senescence in Nucleus Pulposus Cells via ER-Stress Pathway,” Communications Biology 7 (2024): 539.

[24] M. E. Piché, A. Tchernof, and J. P. Després, “Obesity Phenotypes, Diabetes, and Cardiovascular Diseases,” Circulation Research 126, no. 11 (2020): 1477-1500.

[25] Y. Chen, H. Jiang, Z. Zhan, et al., “Restoration of Lipid Homeostasis Between TG and PE by the LXRα-ATGL/EPT1 Axis Ameliorates Hepatosteatosis,” Cell Death & Disease 14, no. 2 (2023): 85.

[26] D. Xu, L. Liu, Y. Zhao, et al., “Melatonin Protects Mouse Testes From Palmitic Acid-Induced Lipotoxicity by Attenuating Oxidative Stress and DNA Damage in a SIRT1-Dependent Manner,” Journal of Pineal Research 69, no. 4 (2020): e12690, https://doi.org/10.1111/jpi.12690.

[27] Y. Mao, W. Luo, L. Zhang, et al., “STING-IRF3 Triggers Endothelial Inflammation in Response to Free Fatty Acid-Induced Mitochondrial Damage in Diet-Induced Obesity,” Arteriosclerosis, Thrombosis, and Vascular Biology 37 (2017): 920-929.

[28] D. Guo, C. Lin, Y. Lu, et al., “FABP4 Secreted by M1-Polarized Macrophages Promotes Synovitis and Angiogenesis to Exacerbate Rheumatoid Arthritis,” Bone Research 10, no. 1 (2022): 45, https://doi.org/10.1038/s41413-022-00211-2.

[29] X. Y. Lu, X. J. Shi, A. Hu, et al., “Feeding Induces Cholesterol Biosynthesis via the mTORC1-USP20-HMGCR Axis,” Nature 588, no. 7838 (2020): 479-484.

[30] D. Yu, N. E. Richardson, C. L. Green, et al., “The Adverse Metabolic Effects of Branched-Chain Amino Acids Are Mediated by Isoleucine and Valine,” Cell Metabolism 33, no. 5 (2021): 905-922.e6.

[31] H. Swahn, J. Mertens, M. Olmer, et al., “Shared and Compartment-Specific Processes in Nucleus Pulposus and Annulus Fibrosus During Intervertebral Disc Degeneration,” Advanced Science (Weinh) 11, no. 17 (2024): e2309032.

[32] D. Samartzis, J. Karppinen, D. Chan, K. D. Luk, and K. M. Cheung, “The Association of Lumbar Intervertebral Disc Degeneration on Magnetic Resonance Imaging With Body Mass Index in Overweight and Obese Adults: A Population-Based Study,” Arthritis and Rheumatism 64, no. 5 (2012): 1488-1496.

[33] X. Xu, X. Li, and W. Wu, “Association Between Overweight or Obesity and Lumbar Disk Diseases: A Meta-Analysis,” Journal of Spinal Disorders & Techniques 28, no. 10 (2015): 370-376.

[34] T. Videman, L. E. Gibbons, J. Kaprio, and M. C. Battié, “Challenging the Cumulative Injury Model: Positive Effects of Greater Body Mass on Disc Degeneration,” Spine Journal 10, no. 1 (2010): 26-31.

[35] G. Desoye and E. Herrera, “Adipose Tissue Development and Lipid Metabolism in the Human Fetus: The 2020 Perspective Focusing on Maternal Diabetes and Obesity,” Progress in Lipid Research 81 (2021): 101082.

[36] Z. A. Ceja-Galicia, C. Cespedes-Acuña, and M. El-Hafidi, “Protection Strategies Against Palmitic Acid-Induced Lipotoxicity in Metabolic Syndrome and Related Diseases,” International Journal of Molecular Sciences 26 (2025): 788.

[37] T. Garin-Shkolnik, A. Rudich, G. S. Hotamisligil, and M. Rubinstein, “FABP4 Attenuates PPARγ and Adipogenesis and Is Inversely Correlated With PPARγ in Adipose Tissues,” Diabetes 63, no. 3 (2014): 900-911.

[38] A. W. Tso, A. Xu, P. C. Sham, et al., “Serum Adipocyte Fatty Acid Binding Protein as a New Biomarker Predicting the Development of Type 2 Diabetes: A 10-Year Prospective Study in a Chinese Cohort,” Diabetes Care 30, no. 10 (2007): 2667-2672, https://doi.org/10.2337/dc07-0413.

[39] R. Rodríguez-Calvo, J. Girona, M. Rodríguez, et al., “Fatty Acid Binding Protein 4 (FABP4) as a Potential Biomarker Reflecting Myocardial Lipid Storage in Type 2 Diabetes,” Metabolism 96 (2019): 12-21.

[40] S. Chen, J. Du, W. Zhao, et al., “Elevated Expression of FABP4 Is Associated With Disease Activity in Rheumatoid Arthritis Patients,” Biomarkers in Medicine 14, no. 15 (2020): 1405-1413.

[41] K. Yang, Q. Xie, J. Liang, et al., “Identification of Andrographolide as a Novel FABP4 Inhibitor for Osteoarthritis Treatment,” Phytomedicine 118 (2023): 154939.

[42] S. Ahmad, H. Khan, Z. Siddiqui, et al., “AGEs, RAGEs and s-RAGE; Friend or Foe for Cancer,” Seminars in Cancer Biology 49 (2018): 44-55.

[43] Z. Q. Wang, L. L. Jing, J. C. Yan, et al., “Role of AGEs in the Progression and Regression of Atherosclerotic Plaques,” Glycoconjugate Journal 35, no. 5 (2018): 443-450.

[44] C. Tseng, B. Chen, Y. Han, et al., “Advanced Glycation End Products Promote Intervertebral Disc Degeneration by Transactivation of Matrix Metallopeptidase Genes,” Osteoarthritis and Cartilage 32, no. 2 (2024): 187-199.

[45] R. Luo, Y. Song, Z. Liao, et al., “Impaired Calcium Homeostasis via Advanced Glycation End Products Promotes Apoptosis Through Endoplasmic Reticulum Stress in Human Nucleus Pulposus Cells and Exacerbates Intervertebral Disc Degeneration in Rats,” FEBS Journal 286, no. 21 (2019): 4356-4373.

[46] J. D. Glaeser, D. Ju, W. Tawackoli, et al., “Advanced Glycation End Product Inhibitor Pyridoxamine Attenuates IVD Degeneration in Type 2 Diabetic Rats,” International Journal of Molecular Sciences 21, no. 24 (2020): 9709.

[47] X. Luo, L. Huan, F. Lin, et al., “Ulinastatin Ameliorates IL-1β-Induced Cell Dysfunction in Human Nucleus Pulposus Cells via Nrf2/NF-κB Pathway,” Oxidative Medicine and Cellular Longevity 2021 (2021): 5558687.

[48] F. Li, X. Sun, B. Zheng, et al., “Arginase II Promotes Intervertebral Disc Degeneration Through Exacerbating Senescence and Apoptosis Caused by Oxidative Stress and Inflammation via the NF-κB Pathway,” Frontiers in Cell and Development Biology 9 (2021): 737809.

[49] G. Z. Zhang, M. Q. Liu, H. W. Chen, et al., “NF-κB Signalling Pathways in Nucleus Pulposus Cell Function and Intervertebral Disc Degeneration,” Cell Proliferation 54, no. 7 (2021): e13057, https://doi.org/10.1111/cpr.13057.

[50] M. Ito, T. Yurube, K. Kakutani, et al., “Selective Interference of mTORC1/RAPTOR Protects Against Human Disc Cellular Apoptosis, Senescence, and Extracellular Matrix Catabolism With Akt and Autophagy Induction,” Osteoarthritis and Cartilage 25, no. 12 (2017): 2134-2146.

[51] Y. Kakiuchi, T. Yurube, K. Kakutani, et al., “Pharmacological Inhibition of mTORC1 but Not mTORC2 Protects Against Human Disc Cellular Apoptosis, Senescence, and Extracellular Matrix Catabolism Through Akt and Autophagy Induction,” Osteoarthritis and Cartilage 27, no. 6 (2019): 965-976, https://doi.org/10.1016/j.joca.2019.01.009.

[52] T. Yurube, W. J. Buchser, Z. Zhang, et al., “Rapamycin Mitigates Inflammation-Mediated Disc Matrix Homeostatic Imbalance by Inhibiting mTORC1 and Inducing Autophagy Through Akt Activation,” JOR Spine 7, no. 1 (2024): e1303.

[53] V. D. D'Agati, A. Chagnac, A. P. de Vries, et al., “Obesity-Related Glomerulopathy: Clinical and Pathologic Characteristics and Pathogenesis,” Nature Reviews. Nephrology 12, no. 8 (2016): 453-471.

[54] Y. Li, Y. Cheng, Y. Zhou, et al., “High Fat Diet-Induced Obesity Leads to Depressive and Anxiety-Like Behaviors in Mice via AMPK/mTOR-Mediated Autophagy,” Experimental Neurology 348 (2022): 113949.

[55] Y. Y. Yi, H. Chen, S. B. Zhang, H. W. Xu, X. Y. Fang, and S. J. Wang, “Exogenous Klotho Ameliorates Extracellular Matrix Degradation and Angiogenesis in Intervertebral Disc Degeneration via Inhibition of the Rac1/PAK1/MMP-2 Signaling Axis,” Mechanisms of Ageing and Development 207 (2022): 111715.

[56] J. M. Lee, J. Y. Song, M. Baek, et al., “Interleukin-1β Induces Angiogenesis and Innervation in Human Intervertebral Disc Degeneration,” Journal of Orthopaedic Research 29, no. 2 (2011): 265-269.

[57] B. Zheng, S. Li, Y. Xiang, et al., “Netrin-1 Mediates Nerve Innervation and Angiogenesis Leading to Discogenic Pain,” Journal of Orthopaedic Translation 39 (2023): 21-33.

[58] D. Fukumura, J. Kloepper, Z. Amoozgar, D. G. Duda, and R. K. Jain, “Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges,” Nature Reviews. Clinical Oncology 15, no. 5 (2018): 325-340.

[59] C. Zhang, Y. Lin, H. Li, et al., “Fatty Acid Binding Protein 4 (FABP4) Induces Chondrocyte Degeneration via Activation of the NF-κb Signaling Pathway,” FASEB Journal 38 (2024): e23347.

[60] Y. Qin, W. Li, J. Liu, et al., “Andrographolide Ameliorates Sepsis-Induced Acute Lung Injury by Promoting Autophagy in Alveolar Macrophages via the RAGE/PI3K/AKT/mTOR Pathway,” International Immunopharmacology 139 (2024): 112719.

[61] S. Laouirem, A. Sannier, E. Norkowski, et al., “Endothelial Fatty Liver Binding Protein 4: A New Targetable Mediator in Hepatocellular Carcinoma Related to Metabolic Syndrome,” Oncogene 38, no. 16 (2019): 3033-3046.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.